

Invitation to presentation of Xbrane Biopharma's year-end report, 2020.

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on February 26, 2021, at 10.00 a.m. CET. Xbrane will publish the company's year-end report 2020, on Friday February 26, 2021, at 8.00 a.m. CET. Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present Xbrane and comment on the year-end 2020, followed by a Q&A session. The presentation will be in English. To attend, please follow the link or dial-in at one of the numbers below:

Web link:

<https://edge.media-server.com/mmc/p/p4j8x94s>

Standard international: +44 (0) 2071 928338

UK (Local): +44 (0) 8444819752

UK (Tollfree): 08002796619

Sweden (Local): +46 (0) 856618467

Sweden (TollFree): 0200125160

US (Local): +1 6467413167

US (TollFree): +1 8778709135

Confirmation Code: 9064055

Contacts

Martin Åmark, CEO

M: +46 (0) 763-093 777

E: martin.amark@xbrane.com

Anette Lindqvist, CFO / IR

M: +46 (0) 763 256 090

E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane, a Lucentis® biosimilar candidate, addresses the SEK 106 billions ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally three biosimilars in its pipeline targeting SEK 100 billions in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.

Press Release
24 February 2021 13:00:00 CET



Attachments

[Invitation to presentation of Xbrane Biopharma's year-end report, 2020.](#)